Innovation Pharmaceuticals Inc. (IPIX)
Market Cap | 111.68M |
Revenue (ttm) | 23,000 |
Net Income (ttm) | -9.82M |
Shares Out | 418.07M |
EPS (ttm) | -0.03 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Dividend Yield | n/a |
Trading Day | April 16 |
Last Price | $0.2575 |
Previous Close | $0.2600 |
Change ($) | -0.0025 |
Change (%) | -0.96% |
Day's Open | 0.2689 |
Day's Range | 0.2530 - 0.2699 |
Day's Volume | 745,440 |
52-Week Range | 0.1160 - 0.6500 |
WAKEFIELD, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that Brilacidin, the Company's d...
WAKEFIELD, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that antiviral data related to B...
WAKEFIELD, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that an independent Data Monitor...
WAKEFIELD, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report today that a Machine Learni...
WAKEFIELD, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today reports that eight sites are now participa...
WAKEFIELD, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announces today that the Company's Phase 2 clinic...
Phase 2 clinical trial of Brilacidin for COVID-19 anticipated to commence this month Phase 2 clinical trial of Brilacidin for COVID-19 anticipated to commence this month
WAKEFIELD, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces additional independent preliminar...
About IPIX
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. It develops Brilacidin, a lead drug compound for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company also develops Kevetrin, a lead anti-cancer compound for treating ovarian cancer. It has license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Cha... [Read more...]
Industry Biotechnology | |
Stock Exchange OTCMKTS | Ticker Symbol IPIX |